Radiation Recall

 

Radiation recall is a severe skin reaction that occurs when certain chemotherapy drugs are administered during or soon after radiation treatment. The rash appears like a severe sunburn. Treatment generally consists of corticosteroids to reduce inflammation, and rarely, chemotherapy is delayed until the skin heals.

What is radiation recall?

Radiation recall is a severe skin reaction that develops when chemotherapy is administered during or soon after radiation treatment. It usually appears on the area of skin where the radiation was administered several weeks to months after the radiation was administered.

What causes radiation recall?

The chemotherapy drugs that have been reported to cause radiation recall in more than 10 percent of patients include:

  • Cosmegen® (actinomycin)
  • Adriamycin® (doxorubicin)
  • Rheumatrex® (methotrexate)
  • 5-FU (fluorouracil)
  • Hydrea® (hydroxyurea)
  • Taxol® (paclitaxel)
  • Doxil® (liposomal doxorubicin)

What are the symptoms of radiation recall?

Radiation recall is a rash that appears like a severe sunburn. It is characterized by one or more of the following:

  • Redness
  • Tenderness
  • Swelling
  • Wet sores
  • Peeling skin
  • Discoloration after the skin has healed

What is the treatment for radiation recall?

In some cases, symptoms may be severe enough that chemotherapy may have to be delayed until your skin heals. Usually, your doctor will try to give you medication to reduce the inflammation so that you can continue receiving the chemotherapy. Corticosteroids, in the form of a pill or a cream, may be prescribed for this purpose.

What else can I do?

It is very important to protect the skin that is irritated:

  • Stay out of the sun
  • Use sunscreens when you must be exposed
  • Avoid tanning beds
  • Wear loose, nonrestrictive clothing

This content was last modified on August 24, 2007 .
Latest Cancer News
Obesity Linked with Worse Colon Cancer Outcomes

March 16, 2010 — Researchers from the Mayo Clinic have reported that obese colon cancer patients have a higher risk of cancer recurrence and death than healthy-weight patients. The results of this study were published in the March 15, 2010 issue of Clinical Cancer Research.

Iressa® plus Arimidex® Improves Progression-free Survival in Patients with Metastatic Breast Cancer

March 16, 2010 — Researchers from the M. D. Anderson Cancer Center have reported that the addition of Iressa® (gefitinib) to Arimidex® (anastrozole) improves progression-free survival (PFS) in postmenopausal women with hormone receptor-positive metastatic breast cancer. The details of this study were published in the March 15, 2010 issue of Clinical Cancer Research.

Children and Teens Have Better NHL Survival than Young Adults

March 16, 2010 — Researchers from the National Institutes of Health have reported that children and teens with non-Hodgkin lymphoma (NHL) have better survival than young adults. These results were published in the March 2010 issue of the Archives of Pediatrics and Adolescent Medicine.

Select news items provided by Reuters Health